Aguilar-Guerra TL, Fajardo-Díaz EM, Gorry C

Idioma: Ingles.
Referencias bibliográficas: 3
Paginas: 9-14
Archivo PDF: 370.86 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Frank M. Cuba says second COVID-19 vaccine Soberana 2 boasts 91.2% effi cacy[Internet]. London: Reuters; 2021 Jul 8 [cited 2021 Jul 9]. Available at: https://www.reuters.com/business/healthcare-pharmaceuticals/cuba-says-second-covid-vaccine-soberana-2-boasts-912-effi cacy-2021-07-09/

2. Valdes-Balbin Y, Santana-Mederos D, Quintero L, Fernández S, RodríguezL, Sanchez-Ramirez B, et al. SARS-CoV-2 RBD-Tetanus Toxoid ConjugateVaccine Induces a Strong Neutralizing Immunity in Pre-Clinical Studies. ACSChem Biol [Internet]. 2021 Jul 4 [cited 2021 Jul 7]. Available at: https://pubs.acs.org/doi/10.1021/acschembio.1c00272

3. Previous MEDICC Review articles about Cuba’s clinical trial regulatory authority andprocess include:http://mediccreview.org/science-at-the-service-of-public-health-rafael-perez-cristia-md-phd-center-for-state-control-of-medicines-and-medical-devices/https://mediccreview.org/the-abcs-of-clinical-trials-in-cuba/https://mediccreview.org/covid-19-requires-innovation-regulation-and-rigor-arteaga/